Inhibrx reports FY2025 net loss $140.1M; cash $124.2M plus $75M debt draw

Inhibrx Biosciences, Inc.

Net loss FY2025: $140.1M ($9.04/share), vs FY2024 net income $1.7B from 101 Transaction gain.
Cash $124.2M at Dec 31, 2025; received $75M gross proceeds from Oxford Finance on Mar 18, 2026.
R&D expense $113M (down 44% YoY); G&A $23.3M (down 82% YoY) due to lower clinical costs and prior-year transaction expenses.
ozekibart BLA submission for chondrosarcoma expected early Q2 2026; PFS data for CRC expansion Q2 2026.
INBRX-106: interim ORR data from Phase 2/3 HNSCC trial expected Q2 2026; PFS data at ESMO Q4 2026.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Inhibrx Biosciences, Inc. reported the fourth quarter and fiscal year 2025 results: net income Net loss was $32.8 million during the fourth quarter of 2025, or $2.11 per share, basic and diluted; Net loss was $140.1.

Period: the fourth quarter and fiscal year 2025
Net income: Net loss was $32.8 million during the fourth quarter of 2025, or $2.11 per share, basic and diluted; Net loss was $140.1
Result: reported results

Exact text from the filing

Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results

View on SEC.gov

Browse all earnings releases →

Inhibrx Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0002007919-26-000007

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.